Evidence map›Paper›PMID 29306853›Full record

ArticleBMJ case reports2018

Management of homozygous familial hypercholesterolaemia in two brothers.

José Real, Cristina Arbona, Rosa Goterris, Juan Francisco Ascaso

Open access · hybridAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.9field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Novel therapeutic targets and agents for pediatric dyslipidemia.Therapeutic advances in endocrinology and metabolism · 2021
    Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

José RealDepartment of Medicine, University of Valencia, Valencia, Spain.
Cristina ArbonaApheresis Unit, Haematology Service, University of Valencia, Valencia, Spain.
Rosa GoterrisApheresis Unit, Haematology Service, University of Valencia, Valencia, Spain.
Juan Francisco AscasoDepartment of Medicine, University of Valencia, Valencia, Spain.
Canadian Apheresis Group · CAUniversitat de València · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Homozygous familial hypercholesterolaemia (HoFH) is a rare, genetic disorder of abnormally high levels of low-density lipoprotein cholesterol (LDL-C) requiring aggressive interventions to retard the evolution of atherosclerotic cardiovascular disease. We treated two brothers (ages 46 years and 47 years) with HoFH with statins, lipoproteinapheresis (LA) and the microsomal triglyceride transfer protein inhibitor lomitapide. Both brothers carried the p.Thr434Arg homozygous

Indexed as

Anticholesteremic AgentsBenzimidazolesHomozygoteHumansHyperlipoproteinemia Type IIMaleMiddle AgedMutationReceptors, LDLSiblingsAnticholesteremic AgentsBenzimidazolesBMS201038LDLR protein, humanReceptors, LDLcongenital disordersendocrine systemlipid disorders

Identifiers

PMID29306853
PMCPMC5775811
OpenAlexW2781992965

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.